Navigation Links
Cadence Pharmaceuticals Reports Second Quarter 2013 Financial Results
Date:7/31/2013

SAN DIEGO, July 31, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today reported financial results for the three and six months ended June 30, 2013.

For the second quarter ended June 30, 2013, Cadence reported net product revenue of $24.7 million, an increase of $13.6 million, or 123% from the second quarter of 2012, and an increase of $1.1 million, or 5% from the first quarter of 2013. Excluding the one-time recognition of $2.6 million of previously deferred net product revenue during the first quarter of 2013, net product revenue for the second quarter of 2013 increased by $3.7 million, or 18%, compared to the first quarter of 2013.

Additional highlights for the second quarter and first half of 2013 included:

  • Net product revenue for the first half of 2013 was $48.3 million, which includes the one-time recognition in the first quarter of 2013 of $2.6 million of previously deferred net product revenue. This represents an increase of $29.2 million, or 153%, compared to the first half of 2012. Excluding the one-time recognition of previously deferred revenue, net product revenue for the first half of 2013 was $45.7 million, which represents an increase of $26.6 million, or 139%, compared to the first half of 2012.
  • As of June 30, 2013, over 4,350 unique end-user customer accounts had ordered OFIRMEV, an increase of 37% from the same time last year. The number of repeat customers increased by 49% during that same time.
  • The average order size per end-user customer increased 27% during the second quarter of 2013 as compared to the second quarter of 2012.
  • The average number of orders per end-user customer increased more than 10% during the second
    '/>"/>

  • SOURCE Cadence Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Cadence Pharmaceuticals Reports First Quarter 2012 Financial Results
    2. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Second Quarter 2012 Financial Results On August 2, 2012
    3. Cadence Pharmaceuticals To Present At The Wedbush PACGROW Life Sciences Management Access Conference In New York City On August 14, 2012
    4. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Stifel Nicolaus Healthcare Conference 2012 In Boston On September 5, 2012
    5. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Third Quarter 2012 Financial Results On November 5, 2012
    6. Cadence Pharmaceuticals Reports Third Quarter 2012 Financial Results
    7. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Piper Jaffray 24th Annual Healthcare Conference In New York City On November 28, 2012
    8. Cadence to Open Finished Medical Device Facility
    9. Cadence Pharmaceuticals to Host Analyst and Investor Day
    10. Cadence Pharmaceuticals Announces Termination of Option Agreement to Acquire Incline Therapeutics, Inc.
    11. Cadence Pharmaceuticals Estimates Fourth Quarter 2012 Net Product Revenue and Provides Full Year 2013 Revenue Guidance
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... WORTH, Texas , Jan. 15, 2014  Humberto C. ... Dermatology Achievement Award" from the Journal of Drugs ... Aesthetic & Clinical Conference (ODAC). The event is January 17-20, ... Florida . The ODAC ...
    (Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. ... a U.S. provisional patent application concerning composition of matter, ... achieve targeted tumor cell death.  This ... noncoding double stranded RNA molecules (VSRNAs) which interfere with ...
    (Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: PharmaPoint: ... Market Analysis to 2022 ... - India Drug Forecast and Market Analysis ...
    Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
    ... Cayenne Medical, Inc., a private sports medicine device ... System, its second generation device for treatment of traumatic ... the 2011 American Orthopaedic Society for Sports Medicine Annual ... Tal David, MD, orthopedic sports medicine specialist, San ...
    ... June 29, 2011 Suneva Medical, a privately-held ... of its core aesthetics injectable business with approval ... its long lasting dermal filler for nasolabial folds ... patients a unique, long-lasting treatment, Bellafill provides physicians ...
    Cached Medicine Technology:Cayenne Medical, Inc. Launches CrossFix® II Meniscal Repair System 2Suneva Medical Announces Canadian Approval of Bellafill™ 2
    (Date:7/9/2014)... in policing injection drug users in Russia might ... , A study, conducted by researchers from Boston ... collaboration with St. Petersburg Pavlov State University, sought ... the health outcomes of a cohort of HIV-positive ... Those who were arrested by police were more ...
    (Date:7/9/2014)... (July 8, 2014) Researchers from Montefiore Medical ... Medicine of Yeshiva University will present new findings ... July 12 July 17 in Copenhagen, Denmark. Data ... could prompt transition from cognitive normality to mild cognitive ... Einstein Aging Study , established in 1980 to ...
    (Date:7/9/2014)... of the most important organs in the human body. ... food properly this is its synthesis function ... this is its detoxification function. Lack of exercise ... damage the liver. The resulting diseased cells can lead ... liver failure. According to the German Liver Foundation, over ...
    (Date:7/9/2014)... July 9, 2014 A study published in the ... Koninck and Robert Bonin, two researchers at Universit Laval, ... using a new method that involves rekindling pain so ... lead to novel means to alleviate chronic pain. , ... Laval and Institut universitaire en sant mentale de Qubec ...
    (Date:7/8/2014)... Department of Defense,s Defense Advanced Research Projects Agency ... to $2.5 million to develop an implantable neural ... neurons within the brain to help restore memory, ... builds on the understanding that memory is a ... the brain encode information, store it and retrieve ...
    Breaking Medicine News(10 mins):Health News:BU researchers relate arrests with HIV risk environment 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:Telemedicine for patients with chronic liver diseases 2Health News:Telemedicine for patients with chronic liver diseases 3Health News:Discovery of a new means to erase pain 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 3
    ... 28 Ronald McDonald House Charities of,the New York ... local graduating high school seniors. Students in the New,York, ... an application at www.rmhc.org or call 1-866-851-3994. ... "The RMHC U.S. Scholarship Program ...
    ... has halved the number of infants born with Down,s ... birth by 30%, according to a study published on ... Australia and New Zealand, are trying to introduce national ... variety of problems because of a lack of consensus ...
    ... appear even in the presence of disinfecting solutions , , THURSDAY, ... lens storage cases, say Israeli researchers who found at least ... 16 people. , The tests of contact lens disinfection solution ... a known cause of severe corneal infections -- was the ...
    ... The Committee for Human,Medicinal Products (CHMP) has ... dosing of 800 mg PREZISTA(R) (darunavir) with ... treatment-naive adults (those who,have never taken HIV ... by Tibotec Pharmaceuticals, and Tibotec, a division ...
    ... Nov. 27 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc.,(NYSE: ... and medical device,research and development outsourcing company with ... Edward Hu, the Company,s Chief Operating,Officer, will present ... Wednesday, December 3, 2008, at 12:00 pm Eastern ...
    ... 26 /PRNewswire-USNewswire/ -- The Pennsylvania Department of ... outpatient, emergency and non-emergency admissions to Commonwealth Medical Center, ... , The department said ... management addresses non-compliance with licensing standards which pose a ...
    Cached Medicine News:Health News:Ronald McDonald House Charities(R) of the New York Tri-State Area to Award Over $500,000 in Scholarships to Graduating High School Seniors 2Health News:New screening halves the number of children born with Down syndrome 2Health News:Contact Lens Cases Often Contaminated 2Health News:European Committee for Human Medicinal Products (CHMP) Issues Positive Opinion for Once-Daily PREZISTA(R) (Darunavir) as Part of Combination Therapy for Treatment-Naive Adults With HIV-1 2Health News:European Committee for Human Medicinal Products (CHMP) Issues Positive Opinion for Once-Daily PREZISTA(R) (Darunavir) as Part of Combination Therapy for Treatment-Naive Adults With HIV-1 3Health News:European Committee for Human Medicinal Products (CHMP) Issues Positive Opinion for Once-Daily PREZISTA(R) (Darunavir) as Part of Combination Therapy for Treatment-Naive Adults With HIV-1 4Health News:WuXi PharmaTech to Present at 20th Annual Piper Jaffray Healthcare Conference 2
    ... nebulizer achieves optimum lung penetration for maximum ... is 1.04-1.10 µ at 6-8 LPM. Latex-free ... ,As the world leader in airway ... assurance of proven technology by offering top ...
    ... OMNI~NEB delivers breakthrough continuous low-flow nebulizer ... precise nozzle technology allows for optimal ... or without Heliox). OMNI~NEB takes on ... both routine and critical care situations. ...
    ... a spill-proof design and effective output, even ... All medical nebulizers are free-standing for easy ... are available., ,All Portex® medication nebulizer ... nebulizers feature consistently fine misting and the ...
    ... Portex® medication nebulizers offer a spill-proof ... up to a 45° angle. All medical ... ,A wide variety of configurations are available., ... latex-free. , ,Portex® medication nebulizers feature ...
    Medicine Products: